Bringing Biologic Drugs to Market | InvestHK
For a drug to be successful, it must undergo vigorous procedures to ensure its efficacy and safety prior to its commercial launch. One that may seem promising during the discovery phase may not perform well in clinical trials if it fails in any part of chemistry, manufacturing and control (CMC) requirements.
Source: https://www.investhk.gov.hk/en/case-studies/bringing-biologic-drugs-market.html See more: https://www.youtube.com/watch?v=H29cU73eE84 |
Taron Solutions is One of The Top 10 Finalist at ATEC’s Startup Competition
Taron Solutions Limited is one of 10 finalist start-up companies chosen from over 80+ international start-ups that participated in Asia Technology Entrepreneurship Conference (ATEC) Startup Competition as a finalist on 09 Nov 19. ATEC is a conference hosted jointly by Harvard, Columbia, Stanford and MIT’s business school and there were many investors present at the competition. The company was the only biotechnology company that was chosen to participate as a finalist, which is a win for not only Taron Solutions, but for the sector in Hong Kong.
CEO of Taron Solutions Alan Chang pitching to the judges at ATEC
For Facebook
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
Taron Solutions 4000 sqft Headquarter and Laboratory for Drug Product Development
Taron Solutions recently completed the headquarter office as well as a state-of-the-art laboratory to facilitate the company’s work on several first-in-class drug and biosimilar drug projects. The laboratory contains different equipment for analytical testing, tissue culture, DNA/Protein detection, and cell detection, process development, and cell banking. Taron plans on establishing ISO9001 standard by 2020.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
Admittance to Hong Kong Science Park Incubio Program
Taron Solutions was successfully admitted into Science Park Incubio program right before Chinese New Year and our move in date for the government subsidized laboratory space is on April 15th.
Taron Solutions are able to carry on some of our advanced R&D and early development service work at this space. Admission in the four year Incubio program include a government grant of HKD 6M paid over the duration of the program. This money can be used towards our Science Park rent and for hiring PhDs. |
Our pilot facility handles early stage bioprocess development up to Phase 2 GMP clinical production
Pilot Facility (Under Construction)
- Size of facility: Approximately 14,000 sq. ft
- Production Scale: Up to 500 L (x 2) with potential to expand
- Our facility handles cell banking, early stage bioprocess development, up to Phase 2 GMP clinical production
- In-house supporting functions such as QC testing labs, GMP warehouse, bio-waste and waste water treatment, utilities (e.g., HVAC, WFI, Clean Steam etc.), process automation systems
- Commencement for GMP manufacturing is ~2 years from the start of facility renovation